Status:
COMPLETED
Comparative Efficacy of Escitalopram Monotherapy and Escitalopram in Adjuvant With Pizotifen in Depressive Disorder
Lead Sponsor:
Riphah International University
Conditions:
Depression
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
To compare the efficacy of escitalopram monotherapy and combination with pizotifen in patients of major depressive disorder(MDD).The levels of depressive symptoms as measured by the Patient Health Que...
Detailed Description
This is an open-label study assessing the comparative efficacy of escitalopram monotherapy and combination with pizotifen in patients of major depressive disorder efficacy of antidepressants in combin...
Eligibility Criteria
Inclusion
- Newly diagnosed patients of Depressive Disorder (PHQ-9).6
- Males and female patients from age 14-70 years.
- The same drug brand will be used throughout the study period.
Exclusion
- Schizophrenia, bipolar disease, active delirium, dementia.
- Pregnant and lactating females.
- History of renal and hepatic disease, myasthenia gravis, gastrointestinal (GI) disease, asthma, cardiovascular disease, and Diabetes Mellitus.
- Mentally handicapped or terminally ill patients.
- Age less than 14 years or above 70 years.
- Patients already taking multiple nutritional supplements.
- Patients taking medications known to interact with the drugs in this study.
Key Trial Info
Start Date :
June 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT06500624
Start Date
June 3 2024
End Date
September 30 2024
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Riphah International University
Rawalpindi, Punjab Province, Pakistan, 00666